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Aim: Tumors related to hereditary susceptibility seem to have an immunosensitive phenotype.Materials &
methods:We conducted a multicenter retrospective study, to investigate if family history of cancer, multi-
ple neoplasms and early onset of cancer could be related to clinical outcomes of anti-PD-1/PD-L1 therapy.
Activity and efficacy data of 211 advanced cancer patients (kidney, non-small-cell lung cancer, melanoma,
urothelium, colorectal and HeN), treated at seven Italian centers with anti-PD-1/PD-L1 agents, were ana-
lyzed. Results: In this preliminary report at multivariate analyses, positive family history of cancer showed
a statistically significant relationship with a better objective response rate (p = 0.0024), disease control
rate (p = 0.0161), median time to treatment failure (p = 0.0203) and median overall survival (p = 0.0221).
Diagnosis of multiple neoplasms significantly correlates only to a better disease control rate, while in-
terestingly non-early onset of cancer and sex (in favor of female patients) showed significant correlation
with a better median overall survival (p = 0.0268 and p = 0.0272, respectively). Conclusion: This pilot study
seems to individuate easily available patient’s features as possible predictive surrogates of clinical benefit
for anti-PD-1/PD-L1 treatments. These preliminary results need to be confirmed with a greater sample
size, in prospective trials with immunotherapy.
First draft submitted: 13 November 2017; Accepted for publication: 21 February 2018; Published online:
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The advent of immune checkpoint inhibitors (ICIs) has led to a revolution in the classical paradigm of cancer care.
In some cases, responses are durable with extended median progression-free survival and median overall survival
(OS) beyond previous standard of care therapies. Although it was initially hoped that ICIs could be ‘The Remedy’ for
many types of cancers, limitations of clinical efficacy of this class of drugs are now emerging, and it is now clear that
a large part of patients does not benefit from ICIs treatment. Currently in use checkpoint inhibitors, all of which
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are monoclonal antibodies, fall into three main classes: anti-CTLA4, which target CTLA4 (such as ipilimumab),
anti-PD-1, which target PD-1 (such as nivolumab and pembrolizumab) and anti-PD-L1, which target PD-L1
(such as atezolizumab, durvalumab and avelumab). Common clinical practice and health economics still suffer a
lack of validated predictive biomarkers to select patients who would benefit from ICIs. PD-L1 protein expression,
evaluated by immunohistochemistry staining, both in tumor and immune cells, has been investigated as a potential
predictive biomarker [1], even in prospective trials [2], but its correlation with ICIs efficacy is still debated [3–5].
Different companion diagnostics, with different immunohistochemistry techniques and platforms were used in
clinical trials, creating difficulties in routine use in clinical practice, despite the efforts of many ‘harmonization’
studies [6–9]. PD-L1 expression is probably a dynamic process influenced by many events, such as previous and/or
concomitant treatments, and has a wide intra-/inter-patient variability [10–12]. The only exception that has led to
reliable and routine use of the test came from positive experience of the Keynote-024 Trial, which established PD-L1
tumor expression >50% as predictive factor of benefit from pembrolizumab in first-line metastatic non-small-cell
lung cancer (NSCLC) setting [13]. A different possible approach to predict immunotherapy efficacy is to analyze
the somatic mutational landscape of the tumor, since a high mutational tumor burden has been shown to correlate
with benefit from immunotherapy [14–16]. Microsatellite instability (MSI), a condition of genetic hypermutability
that results from mismatch repair deficiency, correlates with the number of somatic mutations (especially in MSI-
high cases), and many studies confirmed its positive correlation with ICIs treatment, particularly with anti-PD-1
antibodies [17,18]. MSI is known to be the hallmark of Lynch syndrome (LS), a familial clustering of colorectal
and endometrial cancers. LS is caused by several germline mutations, which result in a defective mismatch repair
and is inherited as dominant autosomal character. Similarly, BRCA1 and 2 mutations, which have been associated
with hereditary breast–ovarian cancer syndrome, may correlate with tumor mutational burden, because of the
homologous recombination repair deficiency. ‘BRCA-like’ phenotype may be more sensitive to anti-PD-1/PD-
L1 [19], thus prospective clinical trials with anti-PD1 for patients with germline BRCA1/2 mutations are currently
ongoing [20]. LS and breast–ovarian cancer syndrome are just two forms of inherited cancer susceptibility; even if
notoriously only about 5–10% of all cancers result directly from germline mutations, we can hypothesize that much
about family cancer syndromes and cancer predisposition is still unknown. Starting from this hypothesis and from
the suggestion that tumors related to syndromes with inherited susceptibility to cancer seem to have an ‘immune-
sensitive phenotype’, we investigated if positive family history of cancer (FHC) and diagnosis of metachronous
and/or synchronous multiple neoplasms (MN), could be used as possible surrogate predictors of clinical benefit for
anti-PD-1/PD-L1 treatments. Furthermore, among families with syndromes of inherited susceptibility to cancer,
patients’ age at cancer diagnosis is typically lower when compared with those of non-hereditary cancer cases [21–23].
Thus, we hypothesized that there could also be a relationship between clinical outcomes with immunotherapy and
early onset (EO) of cancer.
Materials & methods
Patient eligibility
This study evaluated advanced cancer patients who underwent treatment with anti-PD-1/PD-L1, regardless of
the treatment line, at Medical Oncology Units of seven Italian centers. The patients were eligible if they had
histologically confirmed diagnosis of measurable stage IV cancer, with filled records about FHC (positive or
negative), and eventual history of metachronous or synchronous MN. All patients provided written, informed
consent to the treatment with immunotherapy. The procedures followed were in accordance with the ethical
standards of local responsible committees on human experimentation and precepts of Good Clinical Practice.
Study design
A multicenter, retrospective, observational analysis of advanced cancer patients, treated with anti-PD-1 or anti-
PD-L1 monotherapy, as any treatment line, was performed. The aim of this study was to evaluate the correlations
between FHC, MN, EO of cancer and clinical outcomes mostly used in clinical practice: objective response rate
(ORR), disease control rate (DCR), median time to treatment failure (TTF) and median OS. ORR was defined
as the portion of patients experiencing an objective response (complete response or partial response) as best re-
sponse to immunotherapy; DCR was defined as the portion of patients which experienced an objective response
or demonstrated stable disease as best response to treatment. TTF was defined as the time from treatment’s start
to discontinuation for any reason, including disease progression, treatment toxicity, patient preference or death;
OS as the length of time between the beginning of treatment and death or to last contact. The correlations tests
644 Immunotherapy (2018) 10(8) future science group
Family history of cancer, anti-PD1/PD-L1 therapy Preliminary Communication
were performed between clinical outcomes and the following patients’ features: FHC status (positive vs negative),
diagnosis of MN (yes vs no), age at diagnosis (EO vs non-EO), sex (male vs female), Eastern Cooperative Oncology
Group Performance Status (ECOG-PS) (0–1 vs ≥2), number of metastatic sites (including nonregional lymph
nodes metastases) (≤2 vs >2) and treatment line (first vs nonfirst). Responses were evaluated with immune-related
RECIST criteria [24]. χ2 and Fisher’s exact test were used to correlate ORR and DCR with patient’s characteris-
tics [25,26], using the appropriate test according to the sample size in contingency tables for each comparison. Odds
ratio with 95% CI was used to estimate the association between ORR, DCR and predictor variables [27]. In the
multivariate analysis, logistic regression was used to evaluate the role of parameters which resulted to be significant
at the univariate analysis (including FHC and MN status) of ORR and DCR [28]. Median TTF and median OS
were evaluated using the Kaplan–Meier method [29]. Median period of follow-up was calculated according to the
reverse Kaplan–Meier method [30]. Cox proportional hazards model [31] was used to evaluate predictor variables in
univariate and multivariate analysis for median TTF and median OS. Data cut-off period was November 2017.
All statistical analyses were performed using MedCalc Statistical Software version 17.9.7 (MedCalc Software bvba,
Ostend, Belgium; www.medcalc.org; 2017).
Definition of family history of cancer, multiple neoplasms & early onset
Family history was collected in straight and collateral lines, till the fourth degree of relatedness (cousins, children
of parents’ siblings); positive FHC was defined, with at least one diagnosis of cancer found among the relatives.
Diagnosis of metachronous and/or synchronous MN was defined according to the international association of
cancer registry rules [32]. EO of cancer was defined for each primary tumor as follows: for NSCLC ≤60 years [33],
for kidney cancer ≤46 years [34], for urothelial cancer ≤40 years [35–37], for melanoma ≤39 years [38,39], for colorectal
cancer <50 years [40] and <45 years for head and neck carcinomas [41].
Results
Patients’ features
From April 2015 to October 2017, 211 stage IV cancer patients underwent a treatment with anti-PD-1/PD-L1
at 7 Italian centers (Medical Oncology units of: University Hospital of L’Aquila, University Hospital of Chieti,
University Hospital of Parma, University Hospital of Cagliari, Hospital of Frosinone, Pulmonary Oncology Unit
of St. Camillo-Forlanini Hospital of Rome and outpatient cancer care center of Aprilia). Median age was 68 years
(range: 32–85), ECOG-PS 0–1, 179 patients (84.8%), ECOG-PS ≥2, 32 patients (15.2%). Primary tumors were:
renal cell carcinoma 41 patients (19.4%), melanoma 51 patients (24.2%), NSCLC 104 patients (49.3%), urothelial
cancer 10 patients (4.7%), colorectal cancer three patients (1.4%) and head and neck carcinomas two patients
(1%). Administered immunotherapies were: anti-PD-1 in 199 patients (94.3%) (pembrolizumab and nivolumab),
anti-PD-L1 in 12 patients (5.7%) (atezolizumab and avelumab). Anti-PD-1/PD-L1 were administered as first-
line treatment in 36 patients (17.1%), second-line in 103 patients (48.8%), third-line in 45 patients (21.3%),
fourth-line in 19 patients (9.0%) and fifth-line in 8 patients (3.8%). Thirty-two patients (15.2%) had diagnosis
of metachronous MN (no synchronous malignances were reported), 107 patients (50.7%) had positive FHC. The
patients with EO of cancer were 21 (9.9%). All patients’ features, distinct by subgroup, are listed in Table 1.
Activity & efficacy
All activity data are summarized in Table 2. Among 211 patients, 190 (90.1%) were evaluable for activity; the
other 21 patients (9.9%) had not yet evaluated the disease at the time of the data cut-off analysis. ORR and DCR
in overall population were 37.4 and 60.5%, respectively. ORR and DCR among patients with positive FHC were
45.2 and 68.8%, while in patients with negative FHC were 24.7 and 52.6%. ORR and DCR among patients with
diagnosis of MN were 53.8 and 84.6%, while in patients without diagnosis of MN were 31.7 and 56.7%. ORR
and DCR among patients with EO of cancer were 25 and 55%, while in patients with non-EO of cancer were
35.9 and 61.2%. As the forest plot for univariate analysis shows (Figure 1), the variables which were significantly
related to ORR are FHC (p = 0.0032), diagnosis of MN (p = 0.0280) and ECOG-PS (p = 0.0273). At multivariate
analysis, FHC and ECOG-PS were confirmed as independent predictors for ORR (p = 0.0024 and p = 0.0295,
respectively) while not diagnosis of MN (p = 0.0546) (Figure 2). Also regarding DCR, FHC (p = 0.0024), diagnosis
of MN (p = 0.0085) and ECOG-PS (p = 0.0019) were significantly related at univariate analysis (Figure 3), and
they all were confirmed as independent predictors at multivariate analysis (p = 0.0161, p = 0.0217 and p = 0051,
respectively) (Figure 4).
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Table 1. Patients’ features.
Number (%) Positive FHC Negative FHC Positive MN Negative MN EO Non-EO Female Male
Patients (n) 211 107 (50.7) 104 (49.3) 32 (15.2) 179 (84.8) 21 (9.9) 190 (90.1) 69 (32.7) 142 (67.3)
Age, years
Range 32–85 36–85 32–85 45–85 32–85 32–60 43–85 36–85 32–85
Median 68 67 68 74 67 53 68 66 68
ECOG-PS
0–1 179 (84.8) 90 (84.1) 89 (85.6) 31 (96.9) 148 (82.7) 15 (71.4) 164 (86.3) 61 (88.4) 118 (83.1)
≥2 32 (15.2) 17 (15.9) 15 (14.4) 1 (3.1) 31 (17.3) 6 (28.6) 26 (13.7) 8 (11.6) 24 (16.9)
Primary tumor
NSCLC 104 (49.3) 56 (52.3) 48 (46.2) 16 (50.0) 88 (49.1) 18 (85.7) 86 (45.3) 27 (39.1) 77 (54.2)
Melanoma 51 (24.2) 22 (20.6) 29 (27.9) 7 (21.9) 44 (24.6) 2 (9.5) 49 (25.8) 23 (33.3) 28 (19.7)
Renal cell
carcinoma
41 (19.4) 21 (19.6) 20 (19.2) 6 (18.7) 35 (19.6) 1 (4.8) 40 (21.0) 15 (21.7) 26 (18.3)
Urothelial
cancer
10 (4.7) 6 (5.6) 4 (3.8) 3 (9.4) 7 (3.9) - 10 (5.3) 2 (2.9) 8 (5.7)
Colorectal 3 (1.4) 2 (1.9) 1 (1.0) - 3 (1.7) - 3 (1.6) 1 (1.5) 2 (1.4)
HeN 2 (1.0) - 2 (1.9) - 2 (1.1) - 2 (1.0) 1 (1.5) 1 (0.7)
Number of metastases
≤2 112 (53.1) 55 (51.4) 57 (54.8) 20 (62.5) 92 (51.4) 11 (52.4) 101 (53.2) 41 (59.4) 71 (50)
2 99 (46.9) 52 (48.6) 47 (45.2) 12 (37.5) 87 (48.6) 10 (47.6) 89 (46.8) 28 (40.6) 71 (50)
Type of immunotherapy
Anti-PD1 199 (94.3) 100 (93.5) 99 (95.2) 30 (93.7) 169 (94.4) 20 (95.2) 179 (94.2) 66 (95.7) 133 (93.7)
Anti-PDL1 12 (5.7) 7 (6.5) 5 (4.8) 2 (6.3) 10 (5.6) 1 (4.8) 11 (5.8) 3 (4.3) 9 (6.3)
Line of immunotherapy
First
Second
Third
Fourth
Fifth
36 (17.1)
103 (48.8)
45 (21.3)
19 (9.0)
8 (3.8)
17 (15.9)
50 (46.7)
25 (23.4)
11 (10.3)
4 (3.7)
19 (18.3)
53 (51.0)
20 (19.2)
8 (7.7)
4 (3.8)
4 (12.5)
15 (46.9)
8 (25.0)
4 (12.5)
1 (3.1)
32 (17.9)
88 (49.1)
37 (20.7)
15 (8.4)
7 (3.9)
2 (9.5)
12 (57.1)
5 (23.8)
1 (4.8)
1 (4.8)
34 (17.9)
91 (47.9)
40 (21.0)
18 (9.5)
7 (3.7)
16 (23.2)
34 (49.3)
13 (18.8)
5 (7.2)
1 (1.5)
20 (14.1)
69 (48.6)
32 (22.5)
14 (9.9)
7 (4.9)
EO: Early onset; FHC: Family history of cancer; MN: Multiple neoplasm; NSCLC: Non-small-cell lung cancer.
Table 2. Activity data for overall population, and subgroups: positive family history of cancer, negative family history of
cancer, diagnosis of multiple neoplasms, absence of multiple neoplasms, early onset of cancer and non-early onset of
cancer.
Overall FHC Non-FHC MN Non-MN EO Non-EO
Number of
evaluable patients
190 93 97 26 164 20 170
Objective response
rate
37.4 (95%
CI: 26.8–44.1)
45.2 (95%
CI: 32.5–61.0)
24.7 (95%
CI: 15.8–36.8)
53.8 (95%
CI: 29.4–90.3)
31.7 (95%
CI: 23.6–41.5)
25.0 (95%
CI: 8.1–58.3)
35.9 (95%
CI: 27.4–46.1)
Partial/complete
response
66 42 24 14 52 5 61
Disease control
rate
60.5 (95%
CI: 49.9–72.6)
68.8 (95%
CI: 53.0–87.8)
52.6 (95%
CI: 39.1–69.1)
84.6 (95%
CI: 65.1–95.6)*
56.7 (95%
CI: 45.7–69.4)
55.0 (95%
CI: 27.4–98.4)
61.2 (95%
CI: 49.9–74.1)
Stable disease 49 22 28 8 41 6 43
EO: Early onset; FHC: Family history of cancer; MN: Multiple neoplasm.
*Used binomial confidence interval, beacuse of the small sample size of the subgroup.
All the patients were evaluable for efficacy analysis; after a median follow-up of 12.6 months median TTF in overall
population was 7.3 months (95% CI: 5.9–13.1) and median OS was 14.8 months (95% CI: 12.1–21.8) (Figure 5).
At univariate analysis FHC (p = 0.0108), number of metastatic sites (p = 0.0370), ECOG-PS (p < 0.0001) and
sex (p = 0.0301) were significantly related to median TTF, while only FHC (p = 0.0203) (Figure 6) and ECOG-PS
(p < 0.0001) were confirmed as independent predictors at multivariate analysis (Table 3). At univariate analysis
FHC (p = 0.0192), EO of cancer (p = 0.0293), number of metastatic sites (p = 0.0127), ECOG-PS (p < 0.0001)
and sex (p = 0.0051) were significantly related to median OS. FHC (p = 0.0221), ECOG-PS (p < 0.0001), sex
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0.1 1 10 100
Crude OR (95% CI)
Variable Crude OR 95% CI p-value
FHC (negative vs positive)
MN (negative vs positive)
ECOG-PS (≥2 vs 0/1)
Metastatic sites (>2 vs ≤2)
Treatment line (non-first vs first)
Age (early vs non-early onset)
Sex (male vs female)
0.39
0.39
3.52
1.31
1.24
1.67
1.00
0.21–0.73
0.17–0.92
1.16–10.68
0.71–2.39
0.59–2.63
0.58–4.84
0.53–1.88
0.0032*
0.0280*
0.0273*
0.3803
0.5622
0.3349
0.9812
Figure 1. Forest plot graph of univariate analysis of objective response rate.
*Statistically significant.
0.1 1 10 100
Adjusted OR (95% CI)
Variable Adjusted OR 95% CI p-value
FHC (negative vs positive)
MN (negative vs positive)
ECOG-PS (≥2 vs 0/1)
0.37
0.42
3.53
0.19–0.70
0.17–1.01
1.13–11.04
0.0024*
0.0546
0.0295*
Figure 2. Forest plot graph of multivariate analysis of objective response rate.
*Statistically significant.
(p = 0.0272) and EO of cancer (p = 0.0268) were confirmed as independent predictors at multivariate analysis
(Figure 7 & Table 3).
Discussion
The statistically significant correlations, at multivariate analyses, with a benefit in ORR, DCR, median TTF e
(time to treatment failure calculated with kaplan-meier as a survival interval) median OS in favor of positive FHC,
allow us to say that our preliminary results appear to confirm the hypothesis that FHC could be used as predictive
surrogates of clinical benefit to anti-PD-1/PD-L1 therapy. Diagnosis of MN seems to have a less defined role, being
significant related only to DCR. The lack of clinical decisional parameters for immunotherapy choice in advanced
cancer patients makes it challenging to select the best treatment option, especially when not supported by the
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0.01 0.1 1 10
Crude OR (95% CI)
Variable Crude OR 95% CI p-value
0.50 0.27–0.90 0.0224*
0.23 0.07–0.72 0.0085*
3.71 1.56–8.81 0.0019*
1.71 0.95–3.08 0.0719
1.19 0.56–2.53 0.6475
1.28 0.50–3.27 0.5939
1.35 0.72–2.50 0.3426
FHC (negative vs positive)
MN (negative vs positive)
ECOG-PS (≥2 vs 0/1)
Metastatic sites (>2 vs ≤2)
Treatment line (non-first vs first)
Age (early vs non-early onset)
Sex (male vs female)
Figure 3. Forest plot graph of univariate analysis of disease control rate.
*Statistically significant.
0.01 0.1 1 10
Adjusted OR (95% CI)
Variable Adjusted OR 95% CI p-value
0.46 0.24–0.86 0.0161*
0.26 0.08–0.82 0.0217*
3.59 1.46–8.78 0.0051*
FHC (negative vs positive)
MN (negative vs positive)
ECOG-PS (≥2 vs 0/1)
Figure 4. Forest plot graph of multivariate analysis of disease control rate.
*Statistically significant.
presence of an indisputable biomarker. Sometimes, despite offering immune-checkpoint blockade as the probably
best treatment chance for patients, we would like to improve our counseling to inform patients about their chance
of benefit from this therapy. A simple anamnestic parameter, such as FHC, could be easily used, rather than as a
method of selection, to provide a more tailored prediction of treatment outcomes. The hypothesis that there could be
a relationship between clinical benefit with anti-PD-1/PD-L1 therapy and EO of cancer, was unexpectedly denied
by our preliminary data, showing an opposite trend in favor of non-EO of cancer. A possible explanation could
be represented by the higher incidence, among young patients, of very aggressive forms of cancers (such as renal
carcinoma with Xp11.2 translocation). Our result of a statistically significant benefit in OS for patients with non-
EO of cancer compared with whom with EO of cancer meets halfway the opposite evidences of immunosenescence
and residual immunocompetence in elderly patients [42,43]. The statistically significant correlation between sex and
median OS at multivariate analysis, in favor of female patients, remains partly unexplained, and needs further
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Figure 5. Kaplan–Meier survival estimate for median time to treatment failure and median overall survival in
overall population.
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Figure 6. Cox proportional hazard regression survival estimate for positive versus negative family history of cancer
in multivariate analysis.
confirmations. Even if it starts to be known that there are sex-driven differences in immunological responses, which
could bring to different patterns of response to immunotherapy for male and female patients [44], as Table 1 shows,
male and female populations were unbalanced in two important categories: primary tumors (e.g., more NSCLC
among male patients and more melanoma among female patients) and number of metastatic sites.
Among limits of the present study, the retrospective design with its selection biases, could partly explain that
clinical outcomes in overall population are higher than what is generally reported with anti-PD-1/PD-L1 agents.
We must also discuss about the heterogeneity of our population: analyzing in the same time different type of
cancer and different treatment lines could bring us to misestimate results. In contrast of that, Table 1 shows that
patients’ features among patients with positive and negative FHC (ECOG-PS, age, primary tumor, number of
metastases and line of immunotherapy) are well balanced in two subgroups. Even if TTF is a composite end
point, influenced by factors unrelated to efficacy, in our opinion it better fits to our population, which came from
clinical practice and had a spurious nature. We must further cite the lack of centralized imaging revision, and of a
discussion about possible implications of previous/subsequent systemic treatments, which will be better analyzed
in the future development of the study. As we said in the introduction, probably most of the genetic and molecular
mechanisms that underlie inherited susceptibility to cancer are still unknown; in a similar way we still have not
understand the mechanisms that allow some patients to benefit from immunotherapies more than others. For these
reasons, the aim of this preliminary analysis is just to validate the hypothesis, deliberately without biomarkers
assessment; our intention was to find a correlation between FHC and anti-PD1/PD-L1 therapy, “explaining from
afar a phenomenology that we are still not able to describe closely".
We have already planned to extend the study to other centers: with a bigger sample size and a longer follow-up,
we could investigate the role of FHC, diagnosis of MN and EO of cancer in each type of primary tumor and in
patients with homogeneous characteristics (e.g., second-line setting in NSCLC patients), planning a stratification
for ‘burden’ of positive FHC. A tissue bank for biomarkers assessment will be included in the next phase of the
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Table 3. Univariate and multivariate analysis data for time to treatment failure.
Univariate analysis – TTF
Variable (n) HR (95% CI) p-value
FHC
– Positive (107)
Negative (104) 0.61 (0.41–0.89) 0.0108*
MN
– Yes (32)
– No (179) 0.86 (0.49–1.48) 0.5889
Onset
– Early (21)
– Non-early (190) 0.68 (0.38–1.19) 0.1798
Number of metastases
– ≤2 (112)
– 2 (99) 1.48 (1.02–2.15) 0.0370*
ECOG-PS
– 0–1 (179)
– ≥2 (32) 3.23 (2.08–5.01) 0.0001*
Sex
– Male (142)
– Female (69) 1.58 (1.04–2.39) 0.0301*
Treatment line
– First (36)
– Nonfirst (175) 1.04 (0.63–1.70) 0.8682
Multivariate analysis
FHC 0.63 (0.43–0.93) 0.0203*
ECOG-PS 3.16 (1.99–5.01) 0.0001*
Number of metastases 1.17 (0.79–1.73) 0.4127
Sex 1.48 (0.97–2.25) 0.0680
ECOG-PS: Eastern Cooperative Oncology Group Performance Status; FHC: Family history of cancer; MN: Multiple neoplasm; TTF: Time to treatment failure.
*Statistically significant.
study. In case of confirmation of such interesting results, these evidences will deserve to be confirmed also in
prospective trials.
Conclusion
In a scenario with lack of useful factors to make a proper selection among patients to treat or not with anti-
PD-1/PD-L1 therapy, this pilot study seems to individuate easily available patient’s features as possible predictive
surrogates of clinical benefit. These preliminary results need to be confirmed with a greater sample size, in order
to extend the follow-up in each type of primary tumor. Assessment of FHC and MN should be preplanned in
prospective trials with immunotherapy, to provide an external validation of their predictive role (Table 4).
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Figure 7. Cox proportional hazard regression survival estimate for positive versus negative family history of cancer, early onset versus
non-early onset of cancer and male versus female in multivariate analysis.
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